FDA's Warning on Ixchiq Vaccine for Chikungunya

SOURCE www.foxnews.com
The FDA and CDC have recommended pausing the use of the Ixchiq vaccine for chikungunya in adults over 60 due to fatal complications. The vaccine, approved for those aged 18 and older, has caused serious adverse events, including deaths, in older adults.

Key Points

  • FDA and CDC recommend pausing the use of Ixchiq vaccine in adults over 60
  • Ixchiq vaccine contains live, weakened version of chikungunya virus
  • Chikungunya symptoms include fever, severe joint pain, headache, muscle pain, and rash
  • Chikungunya is spread by infected mosquitoes and considered an emerging global health threat

Cons

  • Serious adverse events reported in older adults
  • Deaths from severe complications observed in some cases